Abstract:Non-small cell lung cancer (NSCLC) is still the leading cause of cancer-related deaths worldwide [ [1] Siegel R.L. Miller K.D. Jemal A. Cancer statistics. CA. Cancer J. Clin. 2018; 2018: 7-30 Crossref Scopus (6455) Google Scholar ]. Epidermal growth factor receptor (EGFR) gene mutations as driver oncogenes were first identified in NSCLC in 2004 and common mutations are associated with benefits from tyrosine kinase inhibitors (TKIs) [ 2 Lynch T.J. Bell D.W. Sordella R. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350: 2129-2139 Crossref PubMed Scopus (10005) Google Scholar , 3 Mok T.S. Wu Y.L. Thongprasert S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009; 361: 947-957 Crossref PubMed Scopus (7038) Google Scholar , 4 Maemondo M. Inoue A. Kobayashi K. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010; 362: 2380-2388 Crossref PubMed Scopus (4631) Google Scholar , 5 Rosell R. Carcereny E. Gervais R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2012; 13: 239-246 Abstract Full Text Full Text PDF PubMed Scopus (4445) Google Scholar , 6 Shi Y. Zhang L. Liu X. et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 2013; 14: 953-961 Abstract Full Text Full Text PDF PubMed Scopus (372) Google Scholar ]. Therefore, EGFR mutation detection is a standard method in the management of NSCLC and it is crucial in the management of cases with common or unexpected genotyping results. Approximately 50% of Asian NSCLC patients have EGFR mutations [ [7] Shi Y. Au J.S. Thongprasert S. Srinivasan S. et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J. Thorac. Oncol. 2014; 9: 154-162 Abstract Full Text Full Text PDF PubMed Scopus (928) Google Scholar ]. The most common EGFR mutations are in-frame deletions of exon 19 (45% of all EGFR mutations) and point mutations in exon 21 p.L858R (35% of all EGFR mutations) [ 3 Mok T.S. Wu Y.L. Thongprasert S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009; 361: 947-957 Crossref PubMed Scopus (7038) Google Scholar , 4 Maemondo M. Inoue A. Kobayashi K. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010; 362: 2380-2388 Crossref PubMed Scopus (4631) Google Scholar ]. Clinical trials have indicated that mutations involving exons 18–21, especially for sensitive EGFR mutations, benefit from EGFR-TKI therapy [ 3 Mok T.S. Wu Y.L. Thongprasert S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009; 361: 947-957 Crossref PubMed Scopus (7038) Google Scholar , 5 Rosell R. Carcereny E. Gervais R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2012; 13: 239-246 Abstract Full Text Full Text PDF PubMed Scopus (4445) Google Scholar , 6 Shi Y. Zhang L. Liu X. et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 2013; 14: 953-961 Abstract Full Text Full Text PDF PubMed Scopus (372) Google Scholar ]. A study that explored the efficacy of EGFR-TKIs in patients with uncommon point mutations in exon 21 (at L861) and exon 18 (at G719) showed that the response rate was 57% [ [8] Wu J.Y. Yu C.J. Chang Y.C. et al. Effectiveness of tyrosine kinase inhibitors on uncommon epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin. Cancer Res. 2011; 17: 3812-3821 Crossref PubMed Scopus (381) Google Scholar ]. Exon 19 insertion has been reported as a sensitive mutation in some studies [ 9 He M. Capelletti M. Nafa K. et al. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin. Cancer Res. 2012; 18: 1790-1797 Crossref PubMed Scopus (130) Google Scholar , 10 Park J. Kondo C. Shimizu J. et al. EGFR exon 19 insertions show good response to gefitinib, but short time to progression in Japanese patients. J. Thorac. Oncol. 2014; 9: e10-e11 Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar , 11 Iyevleva A.G. Mitiushkina N.V. Karaseva N.A. et al. Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment. J. Thorac. Oncol. 2014; 9: e31-3 Abstract Full Text Full Text PDF PubMed Scopus (15) Google Scholar , 12 Lin Y.T. Liu Y.N. Wu S.G. et al. Epidermal growth factor receptor tyrosine kinase inhibitor-sensitive exon 19 insertion and exon 20 insertion in patients with advanced non-small-cell lung cancer. Clin. Lung Cancer. 2016; 18: 324-332 Abstract Full Text Full Text PDF PubMed Scopus (29) Google Scholar ]. Its prevalence is rare and it accounts for only 0.5–1% of all EGFR mutations [ 9 He M. Capelletti M. Nafa K. et al. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin. Cancer Res. 2012; 18: 1790-1797 Crossref PubMed Scopus (130) Google Scholar , 12 Lin Y.T. Liu Y.N. Wu S.G. et al. Epidermal growth factor receptor tyrosine kinase inhibitor-sensitive exon 19 insertion and exon 20 insertion in patients with advanced non-small-cell lung cancer. Clin. Lung Cancer. 2016; 18: 324-332 Abstract Full Text Full Text PDF PubMed Scopus (29) Google Scholar ]. Therefore, the clinical efficacy of EGFR-TKIs in patients with exon 19 insertion had never been reported in a large cohort. Also, the clinical responsiveness to EGFR-TKIs in Chinese patients is not clear. Due to the limitations of first-generation testing techniques, not all types of uncommon EGFR mutations are detected. Some EGFR-mutation-negative patients might be false negative and these patients could have poor prognosis because of not receiving EGFR-TKI treatment. With the development of accurate detection technologies, more uncommon EGFR mutations have been detected. Next-generation sequencing (NGS) technology is potentially eligible for emerging molecular therapeutics in NSCLC. Here, we report a case to indicate that advanced NSCLC harboring the EGFR exon 19 insertion (p.I740_K745insIPVAIK) is sensitive to icotinib.

P3.01-009 Clinical Efficacy of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 18 E709X Mutations

Clinical Efficacy of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 18,20 and 21 Uncommon Mutations.

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.

Effects of Icotinib on Advanced Non-Small Cell Lung Cancer with Different EGFR Phenotypes

A Single-Arm, Multicenter, Safety-Monitoring, Phase IV Study of Icotinib in Treating Advanced Non-Small Cell Lung Cancer (NSCLC).

Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China

P2.03-057 Effectiveness of Icotinib on Uncommon EGFR Exon 20 Insert Mutations: A763_Y 764insfqea in Non-Small-Cell Lung Cancer

A Patient of Advanced NSCLC with a New EGFR Exon 19 Insertion Mutation and Its Response to EGFR-TKIs

Real‐world Efficacy and Potential Mechanism of Resistance of Icotinib in Asian Advanced Non‐small Cell Lung Cancer with EGFR Uncommon Mutations: A Multi‐center Study

Icotinib Versus Vinorelbine/platinum As Adjuvant Therapy in Stage II-IIIA Non-Small Cell Lung Cancer with EGFR-mutations: A Multicenter, Randomized, Positive-Controlled, Phase 3, Indication-Expanding Study (EVIDENCE, CCTC-1501).

Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis

Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib

P3.02-027 Lung Adenocarcinoma Patient with EGFR 19 Exon Insert Mutation: I740_K745insIPVAIK and Its Response to Icotinib: A Case Report

P3.01-39 Analysis of Acquired EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer Who Received Icotinib Progress

An Egfr Extracellular Domain Mutation Data In The East Asian Non-Small Cell Lung Cancer Populations And Response To Icotinib: A Multicenter Study.

P3.01-68 Early SBRT to the Primary Tumor May Overcome the Icotinib Resistance in Patients with Advanced NSCLC Harboring EGFR Mutations

Efficacy, Safety and Prognostic Factors Analysis of First-Line Icotinib Treatment in Advanced Non-Small Cell Lung Cancer Patients with Mutated EGFR

1370Tip Befotertinib Versus Icotinib As First-Line Treatment in Patients with Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Controlled Phase III Study

Final Overall Survival and Updated Biomarker Analysis Results from the Randomized Phase Iii Icogen Trial

The Effect of Icotinib Combined with Chemotherapy in Untreated Non-Small-cell Lung Cancer That Harbored EGFR-sensitive Mutations in a Real-Life Setting: a Retrospective Analysis

Phase I Study of Icotinib Hydrochloride (BPI-2009H), an Oral EGFR Tyrosine Kinase Inhibitor, in Patients with Advanced NSCLC and Other Solid Tumors